•  
  •  
  •  
  •  

2026-07-25 10:00:30

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%

Keywords Selected:  BioPharm

Stock Report

  • Gujarat Themis Biosyn Limited to Acquire Japan's MicroBiopharm for INR 1,300 Crores
  • Indegene announces acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma
  • OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
  • Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India
  • Gennova Advances Pathbreaking AI-Enhanced saRNA Vaccine for one of the deadliest known viruses in collaboration with CEPI
  • BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon® in the UK
  • Emcure Pharmaceuticals strengthens its commitment to energy conservation, signs PPA with Sunsure Energy for solar power
  • Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group
  • Cipla EU Ltd to form JV in USA
  • Stelis Biopharma updates on receipt of consideration from Syngene
  • Stelis Biopharma announces closure of its transaction with Syngene International Ltd
  • Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd
  • Evive Biotech and Acrotech Biopharma Announce FDA Approval of Ryzneuta™ for ChemotherapyInduced Neutropenia
  • Stelis Biopharma enters into a binding term sheet with Syngene International Ltd to divest its Unit 3 multi-modal facility
  • Stelis Biopharma's flagship facility receives EIR from the USFDA
  • Stelis Biopharma's CDMO partner receives approval for a key ANDA from the USFDA
  • Evive Enters License Agreement with Acrotech Biopharma to Commercialize Ryzneuta™ in the United States
  • Stelis receives a positive recommendation from EMA granting market authorization for Kauliv™
  • BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
  • Stelis Biopharma's flagship facility receives USFDA nod for Drug Product Capabilities
  • Orchid Pharma Ltd updates on PLI scheme benefits for its subsidiary
  • Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation
  • Sentynl Therapeutics and BridgeBio Pharma announce asset purchase agreement
  • Stelis Biopharma Ltd commissions vaccine manufacturing facility at Bengaluru

Latest Post

  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025